Alaproclate: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 44: | Line 44: | ||
[[Category:Antidepressants]] | [[Category:Antidepressants]] | ||
[[Category:Experimental drugs]] | [[Category:Experimental drugs]] | ||
<gallery> | |||
File:Alaproclate_structure.svg|Structure of Alaproclate | |||
File:Alaproclate-synthesis.svg|Synthesis of Alaproclate | |||
</gallery> | |||
== Alaproclate == | |||
<gallery> | |||
File:Alaproclate_structure.svg|Chemical structure of Alaproclate | |||
File:Alaproclate-synthesis.svg|Synthesis pathway of Alaproclate | |||
</gallery> | |||
Latest revision as of 00:44, 18 February 2025
A selective serotonin reuptake inhibitor
| Alaproclate | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Alaproclate is a pharmacological compound that functions as a selective serotonin reuptake inhibitor (SSRI). It was primarily researched for its potential use as an antidepressant but is not currently marketed for clinical use.
Mechanism of Action[edit]
Alaproclate acts by inhibiting the reuptake of serotonin (5-HT) into the presynaptic neuron, thereby increasing the availability of serotonin in the synaptic cleft. This mechanism is similar to that of other SSRIs, which are commonly used in the treatment of depression and anxiety disorders.
Pharmacokinetics[edit]
The pharmacokinetic profile of alaproclate includes its absorption, distribution, metabolism, and excretion. Alaproclate is administered orally and is absorbed through the gastrointestinal tract. It is metabolized in the liver and excreted primarily through the kidneys.
Synthesis[edit]
The synthesis of alaproclate involves several chemical reactions, starting from basic organic compounds. The process is depicted in the image below:
Clinical Research[edit]
Alaproclate was studied in clinical trials to evaluate its efficacy and safety as an antidepressant. However, it did not progress to become a marketed drug. The reasons for this could include insufficient efficacy, adverse effects, or the development of more effective alternatives.
Side Effects[edit]
As with other SSRIs, alaproclate may cause side effects such as nausea, headache, dizziness, and insomnia. The side effect profile is an important consideration in the development and approval of new pharmacological agents.
Related Compounds[edit]
Alaproclate is related to other SSRIs such as fluoxetine, sertraline, and citalopram. These compounds share a similar mechanism of action but may differ in their pharmacokinetic properties and side effect profiles.
Related pages[edit]
Gallery[edit]
-
Structure of Alaproclate
-
Structure of Alaproclate
-
Synthesis of Alaproclate
Alaproclate[edit]
-
Chemical structure of Alaproclate
-
Synthesis pathway of Alaproclate
